Stryker Corporation (SYK)
Stryker Corporation (SYK) carries a ŷRobot AI score of 68 out of 100. The model's fair value estimate is $294.32, 4.5% above the last close of $281.63. The chart signal reads Bullish.
| Metric | SYK |
|---|---|
| AI score | 68 / 100 |
| Chart signal | Bullish |
| Fair value estimate | $294.32 |
| Upside to fair value | 4.5% |
| Previous close | $281.63 |
| P/E | 28.54 |
| Price / sales | 4.05 |
| Market cap | $108.38B |
| EPS | 9.65 |
| Revenue growth | 10.2% |
| 1-year price change | 5.7% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about SYK
Is SYK overvalued or undervalued right now?
As of Oct 14, 2026, ŷRobot's fair-value model estimates Stryker Corporation (SYK) at $294.32 against a last close of $281.63, implying 4.5% upside to the model's estimate.
Is SYK's chart signal bullish or bearish?
The chart-signal model classifies SYK as Bullish as of Oct 14, 2026, with a signal score of 0.16 on a -1 to 1 scale.
What is SYK's ŷRobot AI score?
SYK scores 68 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 14, 2026.
Is SYK stock expensive on P/E and P/S?
SYK trades at 28.5 times earnings and 4.1 times sales as of Oct 14, 2026.
What does SYK's seasonal forecast show?
ŷRobot's seasonal forecast curve for SYK reads +1.3% at 30 days, +5.3% at 90 days, and +5.7% at one year as of Oct 14, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is SYK growing?
Stryker Corporation's revenue growth is +10.2% and free-cash-flow growth is -1.1% on the latest reported figures.
SYK chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.